Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)
China flag China · Delayed Price · Currency is CNY
35.05
+0.05 (0.14%)
May 8, 2026, 3:00 PM CST

SHA:688319 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
770.44700.13586.1494.29546.68485.29
Other Revenue
4.034.032.751.830.81.86
774.47704.16588.86496.12547.48487.15
Revenue Growth (YoY)
27.90%19.58%18.69%-9.38%12.38%52.18%
Cost of Revenue
70.2963.1729.7736.7343.0128.36
Gross Profit
704.18641559.09459.39504.48458.79
Selling, General & Admin
488.06456.1389.32336.12352.06296.33
Research & Development
123.97132.9134.23114.73121.9956.36
Other Operating Expenses
8.446.053.723.323.553.21
Operating Expenses
633.67608.26537.47455.89489.78364.9
Operating Income
70.5132.7321.623.5114.793.89
Interest Expense
-14.99-14.99-14.46-7.18-5.07-1.23
Interest & Investment Income
1.161.15.363.67.555.19
Currency Exchange Gain (Loss)
-0.01-0.01----
Other Non Operating Income (Expenses)
-2.650.09-0.250.07-0.21-0.19
EBT Excluding Unusual Items
54.0218.9212.28-0.0116.9797.67
Gain (Loss) on Sale of Assets
0.010.01-0.03-0.15-0.15-0.05
Asset Writedown
4.36-----
Other Unusual Items
12.9612.9610.0615.7726.839.57
Pretax Income
71.3631.8922.315.6243.65107.19
Income Tax Expense
15.229.996.584.1817.07-0.77
Earnings From Continuing Operations
56.1421.915.7211.4426.58107.96
Minority Interest in Earnings
0.390.365.046.11--
Net Income
56.5222.2620.7617.5626.58107.96
Net Income to Common
56.5222.2620.7617.5626.58107.96
Net Income Growth
42.45%7.24%18.24%-33.95%-75.38%198.82%
Shares Outstanding (Basic)
405405405405405385
Shares Outstanding (Diluted)
405405405405405385
Shares Change (YoY)
-0.13%0.01%-0.01%0.07%5.22%5.61%
EPS (Basic)
0.140.050.050.040.070.28
EPS (Diluted)
0.140.050.050.040.070.28
EPS Growth
42.63%7.23%18.25%-33.99%-76.61%182.95%
Free Cash Flow
0.246.68-217.05-125.88-225.24-29.75
Free Cash Flow Per Share
0.000.02-0.54-0.31-0.56-0.08
Dividend Per Share
---0.038--
Gross Margin
90.92%91.03%94.94%92.60%92.14%94.18%
Operating Margin
9.10%4.65%3.67%0.71%2.69%19.27%
Profit Margin
7.30%3.16%3.52%3.54%4.85%22.16%
Free Cash Flow Margin
0.03%0.95%-36.86%-25.37%-41.14%-6.11%
EBITDA
105.1566.250.430.6240116.93
EBITDA Margin
13.58%9.40%8.56%6.17%7.31%24.00%
D&A For EBITDA
34.6433.4728.7827.1125.323.04
EBIT
70.5132.7321.623.5114.793.89
EBIT Margin
9.10%4.65%3.67%0.71%2.69%19.27%
Effective Tax Rate
21.33%31.34%29.52%26.74%39.11%-
Revenue as Reported
704.16704.16588.86496.12547.48487.15
Advertising Expenses
-331.88264.73224.9248.75212.96
Source: S&P Global Market Intelligence. Standard template. Financial Sources.